Shukra Pharmaceuticals Limited has announced a series of significant corporate actions, seeking shareholder approval through a postal ballot notice. The company is proposing a substantial increase in its authorized share capital and a generous bonus share issuance, among other resolutions.

Key Proposals

1. Capital Increase: Shukra Pharmaceuticals aims to raise its authorized share capital from Rs. 12.00 crore to Rs. 44.00 crore, a substantial increase that could pave the way for future growth initiatives.

2. Bonus Share Issuance: The company has proposed a 3:1 bonus issue, where shareholders will receive three new shares for every one share held. This move will involve capitalizing Rs. 32.84 crore from the company's securities premium and general reserves.

3. Articles of Association Amendment: To facilitate the bonus issue, Shukra Pharmaceuticals seeks to amend its Articles of Association, allowing the inclusion of general reserve and surplus accounts for bonus share purposes.

4. Managing Director's Remuneration: The company proposes to revise the monthly remuneration of Managing Director Dakshesh Shah to Rs. 8.00 lakh.

Voting Process and Timeline

Current Capital Structure

Shukra Pharmaceuticals' current paid-up capital stands at Rs. 10.95 crore, consisting of 1.09 crore equity shares with a face value of Rs. 10.00 each.

Implications for Shareholders

If approved, the bonus issue will significantly increase the number of shares held by existing shareholders without any additional cost. This move could potentially enhance liquidity in the stock and reward long-term shareholders.

The proposed capital increase and bonus issue reflect the company's confidence in its future prospects and its commitment to creating value for shareholders. However, investors should note that while bonus shares increase the number of shares held, they do not directly impact the overall value of their holdings, as the stock price typically adjusts proportionately.

Shareholders are encouraged to participate in the e-voting process to have their say in these important corporate decisions that could shape the future of Shukra Pharmaceuticals.

Shukra Pharmaceuticals Limited (Shukra Pharma) has announced a significant business development, securing a contract worth ₹24.06 crore for the supply of essential medical products to Afghanistan. This contract marks a notable achievement for the Gujarat-based pharmaceutical company, enhancing its international presence and demonstrating its capability to execute large-scale global healthcare supply projects.

Contract Details

The company received a Letter of Award (LoA) from HSCC (India) Limited, a Government of India Enterprise under the Ministry of Housing & Urban Affairs. HSCC is acting on behalf of the Ministry of External Affairs, Government of India, for this project. The contract involves:

• Supply of Medicines and Diagnostic Kits
• Delivery to the Technical Mission of India, Kabul, Afghanistan
• Comprehensive services including packing, forwarding, insurance, and delivery at the consignee site

Strategic Implications

This contract is significant for Shukra Pharma for several reasons:

1. International Expansion: It strengthens the company's footprint in international markets, particularly in Afghanistan.
2. Government Recognition: The contract, backed by the Government of India, validates Shukra Pharma's capabilities in executing large-scale healthcare supply projects.
3. Business Growth: The management anticipates a positive impact on the company's business growth and brand positioning.
4. Stakeholder Value: The contract is expected to contribute to value creation for the company's stakeholders.

Company Statement

In a corporate announcement to the BSE, Shukra Pharmaceuticals Limited stated, "This order further strengthens Shukra Pharmaceuticals Limited's international presence and reaffirms the Company's capabilities to execute large-scale global healthcare supply projects, especially under Government of India backed initiatives."

Market Impact

Contracts of this nature often have a positive influence on investor sentiment. The successful execution of this contract could potentially open doors for similar opportunities in the future, contributing to the company's long-term growth strategy.

Shukra Pharmaceuticals Limited, with its registered office in Ahmedabad and manufacturing facility in Gandhinagar, Gujarat, continues to expand its operations in the pharmaceutical sector. This latest contract underscores the company's growing role in international healthcare supply chains and its ability to secure significant government-backed projects.